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Abstract 
Review on Familial Myeloproliferative Disorders, 
with data on clinics, and the genes involved. 
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Identity 
Other names 
Familial myeloproliferative neoplasms 
Hereditary erythrocytosis 
Hereditary thrombocytosis 
Note 
Myeloproliferative neoplasms (MPN) are clonal and 
chronic hematological malignancies caused by 
genetic defects that result in overproduction of one 
or several myeloid lineages (erythroïd, 
megakaryocytic and granulocytic lineages). The 
classic MPN or Ph-chromosome-negative MPN 
include polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis 
(PMF).  
Familial MPN are estimated to 2 to 10% according 
to studies.  
They are divided in two overlapping entities:  
- True MPN disorders with germline predisposition 
that are familial clustering of MPN with autosomal 
dominant inheritance and incomplete penetrance. 
These familial cases are indistinguishable from the 
sporadic cases of MPN in terms of clinical features 
and acquired genetic abnormalities.  
- Hereditary MPN-like disorders with clinical 
symptoms of MPN but affecting a single lineage 
involvement.  
They include hereditary thrombocytosis (THPO, 
MPL, JAK2 genes), hereditary erythrocytosis ( 
EPOR, VHL, EGLN1 and EPAS1 genes) and 
hereditary neutrophilia (CSF3R gene).  
These hereditary disorders are non-malignant 
diseases and have distinct features: polyclonal 
hematopoiesis, absence of disease progression and 
autosomal dominant inheritance with complete 
penetrance. 
Inheritance 
Most of familial MPN are compatible with an 
autosomal dominant with incomplete penetrance. 
However, an autosomal recessive pattern has been 
suggested by some authors and could not be 
excluded. 
Clinics 
Phenotype and clinics 
Familial MPN include the three classic MPN or Ph-
chromosome-negative MPN: PV, ET, and PMF. 
Patients with familial MPN have the same clinical 
presentation at diagnosis as patients with sporadic 
MPN.  
They develop the same type of complications 
(thrombosis and hemorrhage) and disease evolution 
(post-PV myelofibrosis, post-ET myelofibrosis, and 
acute myeloid leukemia). The distribution of MPN 
phenotypes within MPN families is homogeneous in 
half of cases (all affected family cases have the same 
MPN). 
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Neoplastic risk 
RISK increased of transformation to acute myeloid 
leukemia (AML). 
Treatment 
The recommendations are those used for sporadic 
MPNS.  
In low-risk patients, phlebotomy in PV patients and 
low-dose aspirin in ET patients are recommended. In 
the presence of risk factors for thrombosis, 
hydroxyurea is used as first-line treatment and 
busulfan or interferon-α as second-line.  
Novel therapies based on JAK2 inhibitors have been 
developed and up to date, are restricted to patients 
with myelofibrosis. 
Evolution 
The main cause of death is the evolution to 
myelofibrosis and AML.  
In familial cases, the incidence annual rate of AML 
has been estimated to 1.25% patients/year for PV 
and 0.68% patients/year for ET. 
Prognosis 
Familial PV: 83% of overall survival at 10 years; 
Familial ET: 84% to 100% of overall survival at 10 
years; Familial PMF: 30% of overall survival at 10 
years. 
Cytogenetics 
Cytogenetics of cancer 
Chromosomal aberrations observed in familial MPN 
are similar to those reported in sporadic cases.  
About two-third of MPN harbor at least one 
chromosomal aberration. Some of them are more 
specifically acquired with disease progression to 
secondary myelofibrosis such as uniparental disomy 
(UPD) of 9p, gain of 1q whereas others are more 
frequently associated with post-MPN acute myeloid 
leukemia such as gain of 1q, deletions of 7q, 5q, 6p, 
7p, 3q and UPD of 19q and 22q. 
Other findings 
MPNs are driven by at least one somatic acquired 
mutation (V617F in JAK2 or mutations in MPL and 
CALR for ET and PMF) and mutations in epigenetic 
regulators such as TET2,  
Several predisposing single-nucleotide 
polymorphism (SNP) such as the JAK2 haplotype 
46/1 (also named GGCC) in JAK2, SNP rs2736100 
in TERT, SNP rs2201862 in MECOM and SNP 
rs9376092 in HBS1L / MYB have been shown to 
play a role in the development of MPN in the general 
population by favoring the acquisition of driver 
mutations. However, except TERT (detailed below, 
none of them explain the familial clustering of MPN. 
Genes involved and 
proteins 
RBBP6 (RB binding protein 6, 
ubiquitin ligase) 
Location 
16p12.1 
DNA/RNA 
Description 
Encoded in 18 exons spanning 33.2 Kb. 
Transcription 
NM_006910.4 encodes the longest transcript. 
Protein 
Description 
Protein of 1792 amino acids. 
Function 
Possible link to P53 function. 
Mutations 
Germinal 
All mutations located in the putative p53-binding 
region. 
ATG2B (Autophagy-related 2B) 
Location 
14q32.2 
Note 
Cooperates with GSKIP, also located in 14q32.2 and 
included in the 700 kb duplication 
NC_000014.9:g.95696766_96390792dup (on 
Assembly GRCh38). 
DNA/RNA 
Description 
Encoded in 42 exons spanning 82 Kb. 
Transcription 
Unique transcript NM_018036. 
 
 
Protein 
Description 
Protein of 2078 amino acids. 
Expression 
Expressed in CD34+ hematopoietic progenitors and 
during erythroïd and megakaryocyte differentiation. 
Function 
Overexpression of ATG2B enhances hematopoietic 
progenitor differentiation, particularly in 
megacaryocytes and cooperates with classical driver 
mutations. 
Mutations 
Note 
Founder defect in families originated from West-
Indies. 
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Germinal 
Head-to-tail 700 kb tandem duplication 
(g.95696766_96390792dup). 
Somatic 
Associated with classical driver mutations such as 
V617F in JAK2, W515L in MPL and 
1099_1050del52 in CALR and with an increased 
frequency of mutations in TET2, IDH1 and IDH2. 
GSKIP (GSK3-beta interaction 
protein) 
Location 
14q32.2 
Note 
Cooperates with ATG2B, also located in 14q32.2 
and included in the 700 kb duplication 
NC_000014.9:g.95696766_96390792dup (on 
Assembly GRCh38). 
DNA/RNA 
Description 
Encoded in 3 exons spanning 7 Kb. 
Transcription 
NM_001271904 encodes the longest transcript; 3 
other transcripts encode the same protein with 
differences in the 5'UTR. 
Protein 
Description 
Protein of 139 amino acids. 
Expression 
in CD34+ hematopoietic progenitors and during 
erythroïd and megakaryocyte differentiation. 
Function 
Overexpression of GSKIP enhances hematopoietic 
progenitor differentiation, particularly of 
megacaryocytes and cooperates with classical driver 
mutations. 
Mutations 
Note 
Founder defect in families originated from West-
Indies. 
Germinal 
Head-to-tail 700 kb tandem duplication 
(g.95696766_96390792dup). 
Somatic 
Associated with classical driver mutations such as 
V617F in JAK2, W515L in MPL and 
1099_1050del52 in CALR and with an increased 
frequency of mutations in TET2, IDH1 and IDH2. 
TERT (telomerase reverse 
transcriptase) 
Location 
5p15.33 
 
DNA/RNA 
Description 
Encoded in 16 exons spanning 42 Kb. 
Transcription 
NM_198253.2 encodes the longest isoform (1); a 
shorter isoform lacking an alternate in-frame exon in 
the middle portion of the coding exon is also 
reported. 
Protein 
Description 
Protein of 1132 amino acids. 
Expression 
Blood cells. 
Function 
Telomerase activity, essential for maintaining 
telomere length. 
Mutations 
Germinal 
Allele C of SNP rs2736100, located in the second 
intron of the TERT gene, is associated with an 
increased risk for MPN (PV, ET and PMF). 
To be noted 
Germline duplication of ATG2B and GSKIP 
predispose with a high penetrance (above 80%) to 
several myeloid malignancies, particularly essential 
thrombocythemia frequently progressing to AML.  
RBBP6 germline gain-of-function mutations mostly 
associated with primary myelofibrosis, observed in 
5% of the familial and 0.6% of the sporadic MPN 
cases. TERT rs2736100_C risk allele is significantly 
associated with familial MPN, whatever the subtype 
(PV, ET and PMF 
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